Vaxart Stock Is Moving Higher After The Bell: What’s Going On?
Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.